Clever Culture Systems (CC5) Company presentation summary

Market opportunity and industry trends

• Pharmaceutical QC automation market is experiencing high growth, with a total addressable market of AU $2.8B and a forecasted 7.2% CAGR over five years.

• Major pharmaceutical companies are investing billions in manufacturing and automation, driving demand for advanced QC solutions.

• Sales pipeline includes 14 of the top 20 global pharma manufacturers, with over 40 qualified leads representing significant revenue potential.

Product innovation and competitive advantage

• APAS® Independence automates culture plate reading, reducing manual errors and improving data integrity.

• Machine learning technology enables faster, more accurate results than traditional microbiologist review.

• System integrates easily into existing workflows and supports high-volume processing, automating up to 1,600 plates per day.

• Outperforms competitors by allowing use of existing incubators and offering greater scalability.

Financial performance and outlook

• Achieved maiden profit of $1.7m in FY25, with product sales of $6.6m and recurring revenue exceeding $1m.

• Cashflow positive, no debt, and $3.1m cash on hand with $1.9m known inflows expected over the next two quarters.

• Revenue model combines upfront Capex and recurring software and service fees, with up to AU $1.5m revenue per instrument over seven years.